Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Assets: 2015-2024

Historic Non-Current Assets for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $101.1 million.

  • Seres Therapeutics' Non-Current Assets fell 13.11% to $91.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.9 million, marking a year-over-year decrease of 13.11%. This contributed to the annual value of $101.1 million for FY2024, which is 44.79% down from last year.
  • As of FY2024, Seres Therapeutics' Non-Current Assets stood at $101.1 million, which was down 44.79% from $183.2 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Non-Current Assets ranged from a high of $183.2 million in FY2023 and a low of $51.2 million during FY2021.
  • Over the past 3 years, Seres Therapeutics' median Non-Current Assets value was $154.0 million (recorded in 2022), while the average stood at $146.1 million.
  • As far as peak fluctuations go, Seres Therapeutics' Non-Current Assets spiked by 200.64% in 2022, and later plummeted by 44.79% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Non-Current Assets stood at $74.2 million in 2020, then crashed by 30.92% to $51.2 million in 2021, then skyrocketed by 200.64% to $154.0 million in 2022, then rose by 18.94% to $183.2 million in 2023, then slumped by 44.79% to $101.1 million in 2024.